Improving targeted therapy for colorectal cancer

改善结直肠癌的靶向治疗

• 批准号: nhmrc : GNT1080498
• 负责人: Dr Michael Griffin
• 金额: $ 93.62万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/improving-targeted-therapy-colorectal-cancer/1345354
• 关键词: Improving; targeted; therapy; colorectal; cancer

Colorectal cancer (CRC) is one of the most common causes of cancer-associated death in the world. We aim to understand why some CRC patients stop responding to EGFR therapy. In particular, we will study small molecules called cytokines that are produced by the tumour microenvironment and determine if the inhibition of these cytokines can over-come the acquired resistance to therapy. Our goal is to identify new ways to improve the current treatment options for CRC patients.

结直肠癌（CRC）是世界上癌症相关死亡的最常见原因之一。我们的目的是了解为什么一些 CRC 患者对 EGFR 治疗停止反应。特别是，我们将研究肿瘤微环境产生的称为细胞因子的小分子，并确定这些细胞因子的抑制是否可以克服获得性的治疗耐药性。我们的目标是找到新的方法来改善 CRC 患者当前的治疗选择。